Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
C
365270
vs
K
KOSPI 200
Over the past 12 months, Curacle Co Ltd has underperformed KOSPI 200, delivering a return of +52% compared to KOSPI 200's +57% growth.
Stocks Performance
365270 vs KOSPI 200
Performance Gap
365270 vs KOSPI 200
Performance By Year
365270 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Curacle Co Ltd
Glance View
Curacle Co Ltd is a South Korean biotechnology company that develops new medicines, mainly drug candidates for diseases tied to blood vessels, inflammation, and fibrosis. Its work is centered on early- and mid-stage research, where it designs and tests compounds that could become prescription drugs. Unlike a drugstore or generic maker, Curacle is focused on creating new treatment candidates rather than selling finished medicines directly. The company’s main customers are not everyday patients. Instead, it works with pharmaceutical partners, research collaborators, and, if a program succeeds, larger drug companies that may license the drug rights. In this kind of business, money usually comes from research agreements, upfront licensing payments, milestone payments, and royalties if a partnered drug reaches the market. What makes Curacle’s role different is that it sits early in the drug value chain. It takes scientific risk to find and validate new molecules, then tries to hand them off to bigger companies with the capital and sales force to run late-stage trials and commercialization. That makes Curacle more of a drug developer and partner than a traditional drug seller.